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Background: Malaria is a mosquito-borne infectious disease caused by Plasmodium spp, which is widespread in 
tropical and subtropical regions of the world. The objective of this study is to evaluate in vivo antimalarial activity of 
propranolol against experimental Plasmodium berghei ANKA (PbA) infection in a mouse model.  
Methods: A total of 36 mice weighing between 15 to 18g were randomly divided into six groups of six mice each. 
Mice in the first group (SAL) were non-infected with P. berghei but received normal saline (control), second group 
(PbA) were mice infected without treatment (control), third group (PRL) were non-infected mice treated with 
propranolol at the dose of 7.5 mg/kg/bid, fourth group (PbA+PRL) were mice infected and treated with same dose 
of propranolol, fifth group (QUN) were non-infected mice treated with quinine at a dose of 20 mg/kg stat, then 10 
mg/kg bid, and sixth group (PbA+QUN) were infected mice treated with quinine. Parasitaemia, physiological 
conditions (cognitive function, temperature) and lethality of infected mice were monitored over 7-day period to 
assess the antimalarial activity of propranolol and quinine. The Y-maze paradigm was used to assess cognitive 
impairment induced by PbA infection. The effects of propranolol on malaria indices and cognitive impairment were 
compared with that of quinine and the control using T-test statistical method.  
Results: Mortality of mice at day 7 in the infected group without treatment (PbA) was 100% (6/6) while mortality 
was 50% (3/6) in infected group treated with propranolol (PbA+PRL) and 33.3% (2/6) in infected group treated 
with quinine (PbA+QUN) (OR=2.000, p=1.000). No mortality was recorded in any of the three groups of uninfected 
mice. Propranolol reduced parasitaemia to a trough level of 1.40±0.07 three days after treatment, comparable to 
trough level of 1.39±0.0633 by quinine but did not reverse PbA-induced hypothermia, which quinine did.  
Conclusion: Propranolol demonstrated in vivo antimalarial activity against experimental PbA infection in mice 
comparable to that of quinine. 
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Abstrait: 
Contexte: Le paludisme est une maladie infectieuse transmise par les moustiques causée par Plasmodium spp, qui 
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antipaludique in vivo du propranolol contre une infection expérimentale à Plasmodium berghei ANKA (PbA) dans un 
modèle murin.                             
Méthodes: Un total de 36 souris pesant entre 15 et 18 g ont été réparties au hasard en six groupes de six souris 
chacun. Les souris du premier groupe (SAL) n'étaient pas infectées par P. berghei mais ont reçu une solution saline 
normale (contrôle), le deuxième groupe (PbA) était des souris infectées sans traitement (contrôle), le troisième 
groupe (PRL) était des souris non infectées traitées par propranolol à la dose de 7,5mg/kg/bid, le quatrième groupe 
(PbA+PRL) étaient des souris infectées et traitées avec la même dose de propranolol, le cinquième groupe (QUN) 
étaient des souris non infectées traitées avec de la quinine à une dose de 20mg/kg stat, puis 10mg/kg bid et le 
sixième groupe (PbA+QUN) étaient des souris infectées traitées avec de la quinine. La parasitémie, les conditions 
physiologiques (fonction cognitive, température) et la létalité des souris infectées ont été surveillées sur une 
période de 7 jours pour évaluer l'activité antipaludique du propranolol et de la quinine. Le paradigme du labyrinthe 
en Y a été utilisé pour évaluer les troubles cognitifs induits par l'infection au PbA. Les effets du propranolol sur les 
indices du paludisme et les troubles cognitifs ont été comparés à ceux de la quinine et du témoin à l'aide de la 
méthode statistique du test T.                                                        
Résultats: La mortalité des souris au jour 7 dans le groupe infecté sans traitement (PbA) était de 100% (6/6) 
tandis que la mortalité était de 50% (3/6) dans le groupe infecté traité avec du propranolol (PbA+PRL) et 33,3% ( 
2/6) dans le groupe infecté traité par la quinine (PbA+QUN) (OR=2.000, p=1.000). Aucune mortalité n'a été 
enregistrée dans aucun des trois groupes de souris non infectées. Le propranolol a réduit la parasitémie à un niveau 
minimum de 1,40±0,07 trois jours après le traitement, comparable au niveau minimum de 1,39±0,0633 de la 
quinine, mais n'a pas inversé l'hypothermie induite par le PbA, ce que la quinine a fait.                      
Conclusion: le propranolol a démontré une activité antipaludique in vivo contre l'infection expérimentale au PbA 
chez la souris comparable à celle de la quinine. 
 




 Malaria is a parasitic disease caused by 
protozoan parasites of the genus Plasmodium, 
which is transmitted by female anopheles’ 
mosquitoes. Only five plasmodia species deve 
lop in humans, these are Plasmodium falci- 
parum, Plasmodium ovale, Plasmodium vivax, 
Plasmodium knowlesi and Plasmodium mala- 
riae. Of these, only Plasmodium vivax and Plas- 
modium ovale have persistent liver forms that 
may lead to relapses after the initial blood 
infection. However, P. falciparum malaria is the 
main species of public health importance as a 
result of its lethality and virulence (1). 
 Cerebral malaria is the most severe 
neurologic complication of infection caused by 
P. falciparum (2) and collectively involves the 
clinical manifestations of malaria that induce 
changes in mental status and coma. It presents 
as acute widespread infection of the brain 
accom- panied by fever (3). Even though this 
type of malaria is most common in children 
living in sub-Saharan Africa, it should be 
considered in any patient with impaired 
consciousness that has recently travelled to a 
malaria endemic area. Cerebral malaria is a 
major cause of acute non-traumatic 
encephalopathy in tropical countries with high 
mortality, and over the past two decades, the 
extent of persistent neuro- cognitive deficits 
after recovery has become very apparent (4).  
 Cerebral malaria is fatal within days if 
left untreated, immediate treatment is there- 
fore crucial (5). Because natural immunity to 
malaria is not fully understood and thus cannot 
yet be artificially imitated by drugs, control and 
prevention strategies are significant, two of 
which include anti-malarial chemotherapy and 
adjunctive measures. Chemotherapy for cere- 
bral malaria now primarily involves the use of 
artesunate (6), and if not available, artemether 
or quinine can be given as alternatives (7). 
However, in most health facilities, quinine still 
finds great use especially because it is still safe 
in the first trimester of pregnancy. Adjunctive 
measures for cerebral malaria include the use 
of anti-pyretics such as paracetamol and anti-
convulsants such as the benzodiazepines. 
 The mature human erythrocyte is a 
terminally differentiated cell that lacks sub-
cellular organelles such as nucleus or secretory 
structures, de-novo protein or lipid biosyn- 
thesis, and does not endocytose its plasma 
membrane (8). Parasite entry into erythrocytes 
is a complex, dynamic process, but it has been 
shown that Gs peptide signaling is involved and 
β-adrenergic blockers inhibit the signaling 
process in vitro (9). It has been documented 
that propranolol, an antagonist of G protein-
coupled β-adrenergic receptors, dampens Gs 
activity in erythrocytes (10). This prevents the 
invasion and growth of the parasite in the 
erythrocyte and hence easy clearance by the 
immune system.    
 Meanwhile, cerebral malaria has been 
attributed to be a major cause of cognitive 
impairment in sub-Saharan Africa (11). This 
impairment has been postulated to be due to 
engorgement of brain microvasculature as a 
result of parasites movement into the brain 
(12). Plasmodium berghei ANKA (PbA) infection 
mimics human cerebral malaria and this strain 
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diffuse encephalopathy arising from cerebral 
malaria (13,14).  
 The objectives of this study are to assess 
in vivo anti-malarial activity of propranolol by 
monitoring end stage symptoms (hypothermia, 
high parasitaemia and lethality) and to eva- 
luate the effects of propranolol on cognitive 
impairment, in a mouse model experimental 
PbA infection.  
 
Materials and method: 
 
Experimental animal study 
 Locally bred apparently healthy albino 
mice of both sexes, 6 to 8 weeks old, with 
weights ranging between 15 g to 18 g were 
used. The animals were obtained from and 
initially housed in a room in the animal house 
of the Department of Pharmacology, Faculty of 
Pharmacy of the Obafemi Awolowo University, 
Ile-Ife. The animals were housed in plastic and 
metal cages that were regularly cleaned and 
beddings changed. The animals were main- 
tained on regular commercial animal feed diet 
and drinking water provided ad libitum. 
 
Experimental drugs 
 The experimental drugs used were 
Quinine hydrochloride (Laborate Pharmaceuti- 
cals, India) and Propranolol (BDH chemicals), 
which were administered intraperitoneally. 
 
Preparation of PbA parasite inoculum  
 The rodent malaria parasite used was a 
quinine sensitive strain, Plasmodium berghei 
ANKA (PbA). The parasite was obtained from 
the Institute of Medical Research and Training, 
University College Hospital (UCH), Ibadan, and 
is used as a model to mimic Plasmodium falci- 
parum that causes cerebral malaria in human 
(13,14). A standard inoculum of 106 parasitized 
erythrocytes was prepared by dilution of blood 
harvested from a donor mouse with normal 
saline by serial persaging.  
 
Experimental study protocol  
 The animals (total of 36 mice) were 
allowed to acclimatize to their new environment 
before randomly dividing them into six groups of 
six mice each. In each group, the mice were 
weighed and marked for identification. The first 
group (SAL) comprised non-infected (control) 
mice which received normal saline, the second 
group (PbA) comprised infected (control) mice 
without treatment,  the third group (PRL) com- 
prised non-infected mice treated with propra- 
nolol at the dose of 7.5 mg/kg/bid (10), the 
fourth group (PbA+PRL) comprised infected 
mice treated with propranolol, the fifth group 
(QUN) comprised non-infected mice treated 
with quinine at a dose of 20 mg/kg stat, then 
10 mg/kg bid (15), and the sixth group 
(PbA+QUN) comprised infected mice treated 
with the same dose of quinine.  
 The experimental study was conducted 
over a period of 7 days while cognitive 
functions of the mice were assessed on day 8. 
Mice were infected on day 0 of the study by 
intraperitoneal administration of the standard 
inoculum of the parasitized erythrocytes. 
Propranolol and quinine were administered 
starting from day 5 to day 7, as cerebral 
malaria is known to develop on day 5 of PbA 
infection in mice (14,16). The non-infected 
mice were also treated with propanol and 
quinine to assess their effects on cognitive 
functions of the mice in the absence of 
parasitaemia. 
 
Assessment of PbA induced lethality in mice 
and effects of propranolol and quinine 
 The lethality of PbA infection was dete- 
rmined by the number of infected mice that 
died in the untreated (PbA) and those treated 
with propranolol (PbA+PRL) and quinine (PbA 
+QUN). 
 
Assessment of PbA induced hypothermia and 
effects of propranolol and quinine 
 Hypothermia, which is infection induced 
observation in mice seen as an end stage 
symptom (16), was determined by measuring 
rectal temperature of mice with an electronic 
thermometer daily for each group during the 
period of the study 
 
Assessment of PbA induced cognitive impair- 
ment and effects of propranolol & quinine 
 The Y-maze, a measure of short-term 
memory (17), was used to assess cognitive 
function in the mice. Each animal was dropped 
in one of the arms of the maze. The movement 
of the mouse into other arms was then 
observed and recorded. The assessment was 
done for six (6) minutes each. The Y-maze 
experiment was done for each group before 
infection and after experimental treatment. 
 
Assessment of PbA parasitaemia and effects of 
propranolol and quinine  
 Parasitaemia was obtained by pre- 
paring slides from thin blood smears made 
from the tail of the mice, fixing with methanol 
and staining with Giemsa. Slides for the 
parasites were prepared for the three groups of 
mice infected with PbA. The stained slide of the 
blood smear was mounted on a binocular 
microscope and a drop of immersion oil applied 
to the slide (15). The 100x objective lens (with 
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scope was used to examine a slide field for 
parasitized and non-parasitized red blood cells. 
In each field, the number of parasitized red 
blood cells was counted, and the total number of 
red blood cells was determined. The slides were 
prepared daily for each group during the period 
of the study. 
 
Statistical analysis 
 The percentage parasitaemia in each 
field was calculated as; % Parasitaemia = 
number of parasitized cells/total number of 
cells (x100). For each slide, 7 fields were 
counted and the average of the 7 fields was 
calculated as the average % Parasitaemia 
(total % parasitaemia/7). The T-test was used 
to compare percentage parasitaemia between 
the infected groups while Fisher Exact was 
used to compare differences in mortality rate 
between groups of treated mice. A p value less 




Effects of propranolol and quinine on lethality 
of infected mice 
 Table 1 shows the lethality of PbA 
infection on the mice in treated and untreated 
groups. Mortality of mice at day 7 in the 
infected group without treatment (PbA) was 
100% (6/6) while mortality was 50% (3/6) in 
the infected group treated with propranolol 
(PbA+PRL) and 33.3% (2/6) in the infected 
group treated with quinine (PbA+QUN). There 
was no mortality of mice in uninfected group 
that received saline (SAL), propranolol (PRL) 




Table 1: Number of surviving animals in the uninfected and infected (with and without treatment) groups of mice  
 
Day 
No of surviving mice in groups of mice 
PbA SAL PbA+PRL PRL PbA+QUN QUN 
Day 3 6 6 6 6 6 6 
Day 4 6 6 6 6 6 6 
Day 5 3 6 5 6 5 6 
Day 6 1 6 4 6 4 6 
Day 7 0 6 3 6 4 6 
PBA = Plasmodium berghei ANKA; SAL = Normal Saline; PRL = Propranolol; QUN = Quinine; PBA+PRL = Plasmodium 
berghei ANKA and Propranolol; PBA+QUN = Plasmodium berghei ANKA and Quinine. 
 
 
Table 2: The average percentage parasitaemia in the three experimentally infected groups of mice with and without treatment 
 














Day 4 7.91±0.0734 8.23±0.0618 7.90±0.1247 
Day 5 9.37±0.1770 4.53±0.2072** 4.12±0.0872** 
Day 6 11.78±0.0000 2.78±0.2148** 3.06±0.1777** 
Day 7 +0 1.40±0.0651** 1.39±0.0633** 
*Significantly different from control at p < 0.05; **Significantly different from control at p <0.01 
PBA – Plasmodium berghei ANKA, PBA+PRL – Plasmodium berghei ANKA + Propranolol, PBA+QUN - Plasmodium berghei ANKA + Quinine 
The average parasitaemia was calculated for the surviving mice on day 5 upward, the parasitaemia for mouse in PbA group on day 6 was 
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Parasitaemia in infected mice  
 Table 2 shows the average percentage 
parasitaemia in the three experimentally infec- 
ted groups of mice with and without treatment. 
Infected mice without treatment (PbA) showed 
increasing parasitaemia, with mortality (50%) 
occurring on day 5 (average parasitaemia of 
9.37±0.1770) and 100% mortality on day 7. 
Infected mice treated with propranolol (PbA+ 
PRL) on day 5 showed a statistically significant 
decrease in average parasitaemia of mice on 
day 5 (4.53±0.2072) from that of day 4 (8.23 
±0.0618) (p<0.05), with mortality of 16.7% 
(1/6) and the lowest parasitaemia was recor- 
ded on day 7 (1.40±0.0651), with mortality of 
50% (3/6). 
 Infected mice treated with quinine 
(PbA+QUN) also showed statistically significant 
decrease in average parasitaemia on day 5 
(4.12±0.0872) from average parasitaemia on 
day 4 (7.90±0.1247), with mortality of 16.7% 
(1/6), and the lowest parasitaemia was recor- 
ded on day 7 (1.39±0.0633), with mortality of 
33.3% (2/6).   
 
Rectal temperature in infected and non-infected 
mice   
 Mice infected with PbA showed reduc- 
tion in rectal temperature as the infection 
progressed compared to the uninfected groups 
(SAL, PRL and QUN) in which the temperature 
did not show any significant variation through- 
out the study period (p>0.05) (Table 3). 
Infected mice treated with propranolol showed 
an increase in rectal temperature from the day 
of treatment as the reduction in rectal temp- 
erature caused by PbA infection from day 3 
was reversed by day 5 propranolol treatment 
on days 6 and 7 of the study.  
 Similarly, infected mice treated with 
quinine showed an increase in rectal temp- 
erature from the day of treatment as the 
reduction in rectal temperature caused by PbA 
infection from day 3 was reversed by quinine 










Mean temperature in groups of mice    
 
























Day 1 36.69±0.1378 36.75±0.1675 36.99±0.2651 36.79±0.4344 36.90±0.1188 36.29±0.3475 
Day 2 36.90±0.1152 36.94±0.0221 36.55±0.1886 35.26±0.2263** 36.58±0.1755 35.42±0.0641** 
Day 3 36.70±0.2563 35.23±0.1030** 36.98±0.1575 35.05±0.1258** 36.59±0.1868 34.93±0.0771** 
Day 4 36.73±0.1145 34.43±0.0844** 36.56±0.1121 33.95±0.1367** 36.59±0.1670 33.40±0.0949** 
Day 5 36.54±0.1485 32.40±0.2000** 36.72±0.0760 34.48±0.1190** 36.40±0.0949 34.49±0.0886 
Day 6 36.70±0.1057 32.00±0.0000** 36.57±0.1301 35.12±0.2252 36.69±0.9610 35.32±0.2278 
Day 7 36.57±0.1605 +0 36.62±1.0955 36.00±0.1528 36.69±0.1177 36.08±0.1652 
**Significantly different from control at p <0.01; *Significantly different from control at p < 0.05; (n=6, mean ± SEM); SAL – Normal Saline, PBA – 
Plasmodium berghei ANKA, PRL – Propranolol, PBA+PRL – Plasmodium berghei ANKA and Propranolol, QUN – Quinine,  PBA+QUN - Plasmodium berghei 
ANKA and Quinine. Average rectal temperature was calculated for the surviving mice on day 5 upward, the rectal temperature for mouse in PbA group on 
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Table 4: Cognitive functions of uninfected and infected (treated and non-treated) groups of mice  
 
Day SAL PbA PRL PbA+ PRL QUN PbA +QUN 
Day 0 
 
61.67±8.6923 74.39±4.6644 56.38±4.4795 73.68±8.3500 64.43±1.8524 74.39±5.8723 
 
  Day 8  74.90±5.242  +0  82.97±7.5013  47.62±9.9143*  67.03±5.2421  57.43±9.7463  
*Significantly different from control at p < 0.05; (n = 6, mean ± SEM); SAL – Normal Saline, PBA – Plasmodium berghei ANKA; PRL – Propranolol, 
PBA+PRL – Plasmodium berghei ANKA and Propranolol, QUN – Quinine, PBA+QUN - Plasmodium berghei ANKA and Quinine. + = no surviving mouse on 
day 7 
 
Effects of propranolol and quinine on cognitive 
functions of infected and uninfected mice 
 The cognitive functions of PbA infected 
untreated mice could not be assessed as 100% 
mortality had occurred on day 7 (Table 4). 
Expectedly, there was no significant change in 
the cognitive functions of the un-infected mice 
that received normal saline. Propranolol (PRL) 
and quinine (QUN) had no effect on the cogni- 
tive function of un-infected mice as there was 
no significant difference between the cogni- 
tive functions before and after treatment. 
 However, there was significant dec- 
rease (p<0.05) in the cognitive functions in 
infected mice treated with propranolol (PbA+ 
PRL), indicating that propranolol did not rev- 
erse the impaired cognitive function caused by 
PbA infection. In contrast, there was no signi- 
ficant difference (p>0.05) in the cognitive 
function of infected mice treated with quinine, 
indicating that quinine protected the mice from 





 In this study, the lethality of P. berghei 
ANKA (PbA) infections in infected untreated 
mice from 50% on day 5, 83.3% on day 6 and 
100% on day 7 confirms this parasite to be 
virulent. This parasite is a laboratory model 
that is often used to mimic P. falciparum 
infection which causes cerebral malaria in human 
(13,14). Lethality can be used as a measure of 
anti-malarial activity of a drug. In this study, 
propranolol reduced mortality in infected mice 
by 50% on day 7 implying that although prop- 
ranolol is effective, its use for treatment of 
cerebral malaria should be initiated as soon as 
possible (5). In comparison, quinine reduced 
mortality of infected mice by 66.7% on day 7 
which confirms the established antimalarial 
property of quinine, especially against cerebral 
malaria (7,15). Propranolol reduced the increa- 
sing parasitaemia in infected mice when 
treated was initiated on day 5 of the study, 
which further confirms its anti-malarial pro- 
perty, and this was comparable to the 
antimalarial property of quinine (15).  
 The use of rectal temperature as a 
parameter is borne out of the fact that one of 
the end stage manifestations of cerebral mal- 
aria is hypothermia (18). In the group infected 
with the parasite, there was a marked signi- 
ficant decrease in the rectal temperature which 
confirms the establishment of PbA infection and 
induced hypothermia from cerebral affectation. 
Our study demonstrated that propranolol rever- 
sed the hypothermia induced by PbA infection 
with recovery of some of the mice, and this 
action was comparable to that of quinine on 
the infected mice as previously established 
(15).  
 The Y-maze is generally acceptable as 
a model to assess cognitive function (17). 
Although cognitive function of the mice in the 
PbA infected group could not be assessed 
because there was 100% mortality of the mice 
on day 7, impaired cognitive function, which 
we believed was caused by the PbA infection in 
the mice as previously reported (11,12), was 
not reversed by propranolol treatment. This 
was demonstrated by significant reduction in 
the cognitive function of the infected mice 
inspite of the propranolol treatment. Propanol 
and quinine also did not show any effect on 
cognitive functions of uninfected animals which 
may imply their safety. However, quinine 
appears to protect the infected mice from 
impaired cognitive function as the cognitive 
function of the PbA infected mice was not 
significantly reduced upon treatment with 
quinine. This protective quinine phenomena 
has similarly been described for P. falciparum 
cerebral malaria in humans (11).  
 
Conclusion:   
 This study demonstrated anti-malarial 
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experiment with comparable antimalarial 
property to that of quinine, a widely used anti-
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